ZA201502838B - Quinazolinone derivatives as parp inhibitors - Google Patents
Quinazolinone derivatives as parp inhibitorsInfo
- Publication number
- ZA201502838B ZA201502838B ZA2015/02838A ZA201502838A ZA201502838B ZA 201502838 B ZA201502838 B ZA 201502838B ZA 2015/02838 A ZA2015/02838 A ZA 2015/02838A ZA 201502838 A ZA201502838 A ZA 201502838A ZA 201502838 B ZA201502838 B ZA 201502838B
- Authority
- ZA
- South Africa
- Prior art keywords
- parp inhibitors
- quinazolinone derivatives
- quinazolinone
- derivatives
- parp
- Prior art date
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006707 | 2012-09-26 | ||
| PCT/EP2013/002577 WO2014048532A1 (en) | 2012-09-26 | 2013-08-27 | Quinazolinone derivatives as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201502838B true ZA201502838B (en) | 2017-11-29 |
Family
ID=47002492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/02838A ZA201502838B (en) | 2012-09-26 | 2015-04-24 | Quinazolinone derivatives as parp inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9388142B2 (enExample) |
| EP (1) | EP2900643B1 (enExample) |
| JP (1) | JP6276769B2 (enExample) |
| KR (1) | KR102200628B1 (enExample) |
| CN (1) | CN104662006B (enExample) |
| AR (1) | AR092670A1 (enExample) |
| AU (1) | AU2013324681B2 (enExample) |
| BR (1) | BR112015006524A8 (enExample) |
| CA (1) | CA2886000C (enExample) |
| ES (1) | ES2654464T3 (enExample) |
| IL (1) | IL237840A (enExample) |
| MX (1) | MX362855B (enExample) |
| RU (1) | RU2650107C2 (enExample) |
| SG (1) | SG11201502120XA (enExample) |
| WO (1) | WO2014048532A1 (enExample) |
| ZA (1) | ZA201502838B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20182096T1 (hr) | 2011-12-22 | 2019-02-22 | Alios Biopharma, Inc. | Supstituirani nukleozidi, nukleotidi i njihovi analozi |
| WO2013132253A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PT2861611T (pt) | 2012-05-25 | 2016-10-11 | Janssen Sciences Ireland Uc | Nucleósidos de espirooxetano de uracilo |
| KR102532198B1 (ko) | 2012-12-21 | 2023-05-11 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
| EP3044221B1 (en) | 2013-09-11 | 2018-02-21 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CA2964113A1 (en) | 2014-10-14 | 2016-04-21 | La Jolla Institute Of Allergy & Immunology | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| CN106432103A (zh) * | 2016-09-14 | 2017-02-22 | 信阳师范学院 | 一种喹唑酮类化合物及其制备方法 |
| WO2018204176A1 (en) * | 2017-05-01 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
| JP7288161B2 (ja) | 2017-12-27 | 2023-06-07 | 国立研究開発法人理化学研究所 | 新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤 |
| EP3733206A4 (en) * | 2017-12-27 | 2021-12-01 | Japanese Foundation For Cancer Research | ANTI-CANCER AGENTS |
| US20220348549A1 (en) * | 2019-08-28 | 2022-11-03 | Hoffmann-La Roche Inc. | Quinazoline compounds for the treatment and prophylaxis of hepatitis b virus disease |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025221809A1 (en) * | 2024-04-16 | 2025-10-23 | Eluciderm Inc. | 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO1999018077A1 (en) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| WO2004014873A1 (ja) * | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| JP2008533020A (ja) * | 2005-03-09 | 2008-08-21 | メルク エンド カムパニー インコーポレーテッド | キナゾリノンｔ型カルシウムチャネル拮抗薬 |
| AU2008223793B2 (en) | 2007-03-08 | 2012-08-23 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| CA2992231C (en) | 2009-03-18 | 2022-03-29 | Resverlogix Corp. | Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| BR112013005223A2 (pt) * | 2010-09-03 | 2016-05-03 | Bayer Ip Gmbh | "pirimidinonas e dihidropirimidinonas fusionadas substituídas." |
-
2013
- 2013-08-27 JP JP2015533466A patent/JP6276769B2/ja active Active
- 2013-08-27 ES ES13756318.5T patent/ES2654464T3/es active Active
- 2013-08-27 BR BR112015006524A patent/BR112015006524A8/pt not_active Application Discontinuation
- 2013-08-27 WO PCT/EP2013/002577 patent/WO2014048532A1/en not_active Ceased
- 2013-08-27 CA CA2886000A patent/CA2886000C/en active Active
- 2013-08-27 CN CN201380050421.9A patent/CN104662006B/zh active Active
- 2013-08-27 EP EP13756318.5A patent/EP2900643B1/en active Active
- 2013-08-27 KR KR1020157010728A patent/KR102200628B1/ko not_active Expired - Fee Related
- 2013-08-27 RU RU2015115576A patent/RU2650107C2/ru active
- 2013-08-27 SG SG11201502120XA patent/SG11201502120XA/en unknown
- 2013-08-27 US US14/431,632 patent/US9388142B2/en active Active
- 2013-08-27 AU AU2013324681A patent/AU2013324681B2/en active Active
- 2013-08-27 MX MX2015003570A patent/MX362855B/es active IP Right Grant
- 2013-09-25 AR ARP130103430A patent/AR092670A1/es active IP Right Grant
-
2015
- 2015-03-19 IL IL237840A patent/IL237840A/en active IP Right Grant
- 2015-04-24 ZA ZA2015/02838A patent/ZA201502838B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015006524A2 (pt) | 2017-07-04 |
| US20150239850A1 (en) | 2015-08-27 |
| WO2014048532A1 (en) | 2014-04-03 |
| IL237840A (en) | 2017-05-29 |
| RU2015115576A (ru) | 2016-11-20 |
| MX362855B (es) | 2019-02-20 |
| CN104662006B (zh) | 2017-10-24 |
| AU2013324681B2 (en) | 2017-08-10 |
| BR112015006524A8 (pt) | 2019-08-20 |
| ES2654464T3 (es) | 2018-02-13 |
| CA2886000A1 (en) | 2014-04-03 |
| HK1210777A1 (en) | 2016-05-06 |
| AU2013324681A1 (en) | 2015-05-07 |
| KR20150063474A (ko) | 2015-06-09 |
| EP2900643A1 (en) | 2015-08-05 |
| JP2015535831A (ja) | 2015-12-17 |
| CN104662006A (zh) | 2015-05-27 |
| JP6276769B2 (ja) | 2018-02-07 |
| US9388142B2 (en) | 2016-07-12 |
| MX2015003570A (es) | 2015-06-22 |
| KR102200628B1 (ko) | 2021-01-08 |
| SG11201502120XA (en) | 2015-04-29 |
| AR092670A1 (es) | 2015-04-29 |
| RU2650107C2 (ru) | 2018-04-09 |
| CA2886000C (en) | 2020-11-10 |
| EP2900643B1 (en) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201502838B (en) | Quinazolinone derivatives as parp inhibitors | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| IL239193A0 (en) | New Benzimidazole Derivatives as Kinase Inhibitors | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| EP2831080A4 (en) | LACTAMES INHIBITORS OF KINASES | |
| IL234183A (en) | The history of pyrazolotriazine as selective kinase antagonists with cyclin dependence | |
| SMT201700291T1 (it) | Benzimidazoli triciclici sostituiti come inibitori della chinasi | |
| IL237475A0 (en) | Pyrlotriazinone derivatives as pi3k inhibitors | |
| GB201211310D0 (en) | CSF-1R kinase inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| SG11201404654SA (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| SI2912032T1 (sl) | Derivati 4-karboksamido-izoindolinona kot selektivni zaviralci PARP-1 | |
| PL2912041T3 (pl) | Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| SG11201406860SA (en) | Quinazolinedione derivative | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| EP2900243A4 (en) | BICYCLIC OXA LACTAM KINASE HEMMER | |
| SG11201501212QA (en) | Quinazoline derivatives and uses thereof as apoptosis inhibitor |